Humacyte Stock Performance
| HUMAW Stock | USD 1.50 0.09 5.66% |
The company retains a Market Volatility (i.e., Beta) of 0.71, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Humacyte's returns are expected to increase less than the market. However, during the bear market, the loss of holding Humacyte is expected to be smaller as well. At this point, Humacyte has a negative expected return of -0.17%. Please make sure to check out Humacyte's information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Humacyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Humacyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
1 | Humacyte, Inc. Is Considered a Good Investment by Brokers Is That True - Zacks Investment Research | 09/18/2024 |
2 | Humacyte, Inc. Increases Yet Falls Behind Market What Investors Need to Know - Yahoo Finance | 09/26/2024 |
3 | Acquisition by Niklason Laura E of 114420 shares of Humacyte at 1.19 subject to Rule 16b-3 | 10/08/2024 |
4 | Humacyte Faces Financial Uncertainty Potential Impact on Share Price and Capital - MSN | 11/19/2024 |
| Begin Period Cash Flow | 149.8 M | |
| Free Cash Flow | -75.6 M |
Humacyte |
Humacyte Relative Risk vs. Return Landscape
If you would invest 198.00 in Humacyte on August 29, 2024 and sell it today you would lose (48.00) from holding Humacyte or give up 24.24% of portfolio value over 90 days. Humacyte is currently producing negative expected returns and takes up 7.2591% volatility of returns over 90 trading days. Put another way, 64% of traded stocks are less volatile than Humacyte, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Humacyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Humacyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Humacyte, and traders can use it to determine the average amount a Humacyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.024
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HUMAW |
Estimated Market Risk
| 7.26 actual daily | 64 64% of assets are less volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Humacyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Humacyte by adding Humacyte to a well-diversified portfolio.
Humacyte Fundamentals Growth
Humacyte Stock prices reflect investors' perceptions of the future prospects and financial health of Humacyte, and Humacyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Humacyte Stock performance.
| Return On Equity | -8.51 | ||||
| Return On Asset | -0.53 | ||||
| EBITDA | (96.46 M) | ||||
| Net Income | (110.78 M) | ||||
| Total Debt | 58.11 M | ||||
| Book Value Per Share | (0.53) X | ||||
| Cash Flow From Operations | (73.31 M) | ||||
| Earnings Per Share | (3.16) X | ||||
| Total Asset | 128.22 M | ||||
| Retained Earnings | (537.31 M) | ||||
| Working Capital | 64.83 M | ||||
About Humacyte Performance
Evaluating Humacyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Humacyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Humacyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (1.58) | (1.50) | |
| Return On Tangible Assets | (0.86) | (0.82) | |
| Return On Capital Employed | (0.91) | (0.96) | |
| Return On Assets | (0.86) | (0.82) | |
| Return On Equity | (8.18) | (7.77) |
Things to note about Humacyte performance evaluation
Checking the ongoing alerts about Humacyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Humacyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Humacyte generated a negative expected return over the last 90 days | |
| Humacyte has high historical volatility and very poor performance | |
| Humacyte may become a speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (110.78 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Humacyte generates negative cash flow from operations | |
| Latest headline from news.google.com: Humacyte Faces Financial Uncertainty Potential Impact on Share Price and Capital - MSN |
- Analyzing Humacyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Humacyte's stock is overvalued or undervalued compared to its peers.
- Examining Humacyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Humacyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Humacyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Humacyte's stock. These opinions can provide insight into Humacyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.